The genetic basis for the inverse relationship between rheumatoid arthritis and schizophrenia

Mansour Zamanpoor1,2 | Hamid Ghaedi1 | Mir Davood Omrani1

1Medical Genetics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Biochemistry, University of Otago, Dunedin, New Zealand

Correspondence
Mir Davood Omrani, Medical Genetics Department, School of Medicine, Shahid Beheshti University of Medical Sciences, Velenjak Ave., Chamran Highway, Tehran, Iran. Email: davood_omrani@sbmu.ac.ir

Funding information
University of Otago, New Zealand

Abstract

Introduction: Rheumatoid arthritis is a common autoimmune disease and schizophrenia is a relatively common and debilitating neurological disorder. There are several common features between rheumatoid arthritis and schizophrenia. The inverse relationship between rheumatoid arthritis and schizophrenia has been replicated in several studies. Despite evidence for an inverse epidemiological relationship and negative correlations for risk between rheumatoid arthritis and schizophrenia, there are no biological data that directly support this inverse relationship.

Materials and Methods: We meta-analyzed the genome-wide association studies to investigate the shared association loci between rheumatoid arthritis and schizophrenia at the genome-wide scale. Rheumatoid arthritis- and schizophrenia-associated loci in most recent genome-wide association studies of rheumatoid arthritis and schizophrenia were tested. Genetic risk score analysis was also conducted to investigate the collective contribution of schizophrenia risk loci to rheumatoid arthritis risk.

Results: Rheumatoid arthritis and schizophrenia meta-genome-wide association study showed a significant peak at the major histocompatibility complex locus on chromosome 6 in both rheumatoid arthritis-schizophrenia meta-genome-wide association study and inverted meta-genome-wide association study datasets. Testing rheumatoid arthritis- and schizophrenia-associated loci outside the human leukocyte antigen region showed no association with both rheumatoid arthritis and schizophrenia at a genome-wide level of significance. Weighted genetic risk scores showed no evidence for a statistically significant association between rheumatoid arthritis and schizophrenia.

Conclusion: The finding of our study is consistent with the role of the major histocompatibility complex locus in the genetic correlation between rheumatoid arthritis and schizophrenia, and suggests that either schizophrenia has an autoimmune basis and/or rheumatoid arthritis has an active neurological component.

KEYWORDS
genetic risk scores, GWAS, meta-analysis, rheumatoid arthritis, schizophrenia
Rheumatoid arthritis (RA; OMIM 180300) is a common autoimmune disease that causes chronic inflammation of the joints (Zamanpoor, 2019). Schizophrenia (OMIM 181500) is a relatively common and debilitating neurological disorder and characterized by chronic psychotic symptoms and psychosocial impairment (Zamanpoor, 2020). The etiologies of both RA and schizophrenia are best explained by a multi-factorial polygenic threshold model that invokes multiple genetic risk factors modified by the environment (Malavia et al., 2017; Smolen, Aletaha, & McInnes, 2016; Zamanpoor, 2019, 2020). Both RA and schizophrenia have a similar estimated point prevalence of 0.46% for RA (Helmick et al., 2008) and lifetime prevalence of 0.48% for schizophrenia (Simeone, Ward, Rotella, Collins, & Windisch, 2015). There are some common etiological factors such as their link with the HLA complex genes and also their association with infectious agents such as T. gondii (Feigenson, Kusnecov, & Silverstein, 2014; Torrey & Yolken, 2001). There is an established negative association between RA and schizophrenia.

Epidemiological and clinical studies have consistently reported a lower prevalence of RA in patients with schizophrenia in comparison with the general population (Chen, Wang, Chiang, Hsu, & Shen, 2019; Ching Lok, Mok, Cheng, & Chi Cheung, 2010; W. Eaton et al., 2004; Feigenson et al., 2014; Gorwood et al., 2004; Malavia et al., 2017; Mittendorfer-Rutz et al., 2019; Ohi et al., 2016; Oken & Schulzer, 1999; Sellgren, Frisell, Lichtenstein, Landen, & Askling, 2014). The risk for developing RA among schizophrenia patients has been estimated to be 30%–50% that of the control group (Feigenson et al., 2014). This has been supported by reduced rates of RA in families with multiple schizophrenia members (Feigenson et al., 2014). Similarly there is a lower risk of developing schizophrenia among individuals with RA (Gorwood et al., 2004). In a Swedish population the relative risks of developing RA in schizophrenia and schizoaffective disorder were significantly decreased (hazard ratio = 0.69; Sellgren et al., 2014).

The inverse relationship between RA and schizophrenia has been replicated in several studies (Chen et al., 2012; Ching Lok et al., 2010; Eaton, Hayward, & Ram, 1992; Gorwood et al., 2004; Mors, Mortensen, & Ewald, 1999; Oken & Schulzer, 1999; Sellgren et al., 2014). The RA and schizophrenia correlation has been highlighted in several publications, as shown in Table 1. Epidemiological studies are inconsistent on the relationship between schizophrenia and RA. Several studies showed less frequent occurrence of RA among schizophrenia cases than would be expected by chance, while other studies have failed to replicate this protective effect of schizophrenia on RA (Euesden, Breen, Farmer, McGuffin, & Lewis, 2015). Meta-analysis across studies showed a significant reduction in prevalence of RA in schizophrenia cases (OR = 0.48, p < 0.0001; Euesden et al., 2015). Polygenic risk scoring in a RA case control study revealed a weak contribution of schizophrenia genetic risk to RA risk (Euesden et al., 2015).

Several psychosocial and biochemical hypotheses such as abnormal tryptophan metabolism, prostaglandin deficiency, and consequences of treatment have been proposed to explain the RA-schizophrenia relationship (Lee et al., 2015). The reduction in comorbidity between RA and schizophrenia and the strong genetic contribution to both disorders suggests that there might be a common genetic pathway responsible for susceptibility to one disorder and at the same time protecting against the other (de la Fontaine et al., 2006). Numerous candidate genes have been suggested for the association between RA and schizophrenia, but the HLA system has been the most studied locus (Gorwood et al., 2004).

Advances in technology provided a new opportunity to further investigate the genetic basis of the RA-schizophrenia relationship (Lee et al., 2015). The meta-analysis of three RA and two schizophrenia GWAS datasets genetically confirmed the small but significant negative correlation (Lee et al., 2015). Associated loci for both RA (101 loci) and schizophrenia (128 loci) exhibit more shared loci than expected by chance (Lee et al., 2015). This could be dominated by the positive correlation between variations in the major histocompatibility complex (MHC) region (Lee et al., 2015). The MHC region is the most associated region in GWAS of schizophrenia. This genetic evidence supports the immune hypothesis that variation within immune genes contributes to schizophrenia (Michel, Schmidt, & Mirnics, 2012; Pouget et al., 2016). HLA class II, containing the HLA-DR4 (DRB1*04) allele of the HLA-DRB1 gene, is the most frequently reported genetic allele in association with schizophrenia (Wright, Nimgaonkar, Donaldson, & Murray, 2001). Associated HLA class II antigens or alleles include HLA-DRB1*0101 and HLA-DRB1*04 (*0401, *0403, *0405, and *0406) that control antibody-mediated immune responses (Wright et al., 2001). HLA-DRB1, including the HLA-DR4 serotype, is associated positively with RA and inversely with schizophrenia (Watanabe et al., 2009). HLA-DRB1 has a well-established effect in RA but its function is more modest in schizophrenia (Lee et al., 2015). This might suggest that HLA-mediated antigen recognition has a different role in RA and schizophrenia (Lee et al., 2015). Therefore, a negative genetic correlation between RA and schizophrenia could be due to the different roles of variants in immune response pathways in different tissues and/or in response to different challenges (Lee et al., 2015).

Understanding this negative correlation between RA and schizophrenia may reveal novel insights into the etiology of both diseases. Identifying genes associated with these disorders increases the understanding of polygenic disease. The putative pathway responsible for the negative correlation...
**TABLE 1** The prevalence of rheumatoid arthritis in schizophrenic patients and controls. All control sets have another psychiatric illness except Eaton et al. (2006) in which controls were free from psychiatric illness.

| Data source                                      | Location                        | Sample size | RA frequency, n (%) | Odds ratio/hazard ratio | p value |
|-------------------------------------------------|---------------------------------|-------------|----------------------|-------------------------|---------|
| Ross, Hay and McDowall (1950)                    | Canada                          | 800         | 0                    | 4 (0.49)                | 0.11 (0.006–2.08) | 0.14    |
| Pilkington (1956)                                | England                         | 130         | 1 (0.77)             | 4 (2.66)                | 0.28 (0.03–2.46)  | 0.25    |
| Mellsop, Koadlow, Syme and Whittingham (1974)    | Australia and New Zealand       | 301         | 0                    | 234 (7.41)              | 0.02 (0.001–0.33) | 0.006   |
| Österberg (1978)                                 | Sweden                          | 62,228      | 16 (0.047)           | 299 (0.10)              | 0.45 (0.28–0.72)  | 0.001   |
| Baldwin (1980)                                   | England                         | 2,314       | 2 (0.09)             | 23 (0.43)               | 0.20 (0.05–0.86)  | 0.03    |
| Mohamed, Merskey, Kazarian and Disney (1982)     | USA                             | 111         | 0                    | 3 (5.88)                | 0.06 (0.003–1.23) | 0.07    |
| Allebeck, Rodvall and Wistedt (1985)             | Sweden                          | 1,190       | 2 (0.17)             | 71 (0.41)               | 0.41 (0.09–1.74)  | 0.22    |
| Oken & Schulzer, 1999                           | Canada                          | 27,630      | 101 (0.11)           | 900 (0.44)              | 0.24 (0.17–0.35)  | 0.001   |
| Oken & Schulzer, 1999                           | USA                             | 1,323       | 1 (0.08)             | 2 (0.30)                | 0.25 (0.02–0.75)  | 0.26    |
| Eaton et al. (2006)                              | Denmark                         | 7,704       | 15 (0.19)            | 336 (0.17)              | 1.15 (0.055–2.5)  | 0.24    |
| Chen et al., 2012                                | Taiwan                          | 10,811      | 30 (0.28)            | 507 (0.47)              | 0.52 (0.35–0.76)  | 0.007   |
| Benros et al. (2014)                             | Denmark                         | 39,364      | 82 (0.21)            | 15,686 (0.41)           | 0.50 (0.40–0.62)  | —       |
| Sellgren et al., 2014                            | Sweden                          | 47,326      | —                    | 157 (0.33)              | 0.69 (0.59–0.80)  | —       |
| Chen et al., 2019                                | Taiwan                          | 58,847      | 21 (0.04)            | 189 (0.08)              | 0.48 (0.31–0.76)  | —       |
between RA and schizophrenia has potential as a therapeutic target. It may be possible to manipulate the putative pathway in such a way that the body is deceived into believing one phenotype is active and thus protected against the other. It is, therefore, important to identify any genes that may be responsible for the link between the two disorders. Our study aimed to investigate genes that play a role in both the autoimmune and neurological systems to find variants responsible for the negative association between RA and schizophrenia.

2  |  MATERIALS AND METHODS

In this study, meta-analysis of the large GWAS datasets were performed using METAL which provides a computationally efficient tool to combine large GWAS datasets (Willer, Li, & Abecasis, 2010). Associated loci of RA and schizophrenia, at a genome-wide level of significance, in most recent GWAS of RA (Okada et al., 2014) and schizophrenia (Li et al., 2017) were tested.

Okada et al. (2014) RA GWAS included 29,880 RA cases and 73,758 controls of European and Asian ancestry. All RA patients were diagnosed by rheumatologists and met the criteria for the diagnosis of RA according to the 1987 American College of Rheumatology classification system. As a result, 42 novel RA-associated loci was discovered and the total RA risk loci at a genome-wide level of significance was increased to 101. The reported heritability for RA risk loci outside of the MHC region was 5.5% and 4.7% in Europeans and Asians, respectively (Okada et al., 2014). Li et al. (2017) schizophrenia GWAS included 43,175 cases and 65,166 controls in total, consisted of the 7,699 cases and 18,327 controls of Chinese ancestry in addition to the schizophrenia working group of the psychiatric genomics consortium (PGC2) data. The reported heritability of schizophrenia explained by GWAS loci was only 3.5% (Li et al., 2017).

Two inverse-variance weighted fixed-effects meta-GWAS were performed to combine the RA and the schizophrenia GWAS datasets using the R package meta. The first meta-GWAS was performed by combining the RA and schizophrenia datasets. In order to perform the second meta-GWAS (inverted meta-GWAS), the OR values of the schizophrenia data were inverted and then, combined with the RA data. Before meta-analysis, the RA and the schizophrenia GWAS datasets underwent extensive quality control. Monomorphic SNPs and SNPs with minor allele frequency <0.01 and HWE $p < 5 \times 10^{-8}$ were filtered and the remaining SNPs were used for subsequent analyses. Consequently, data for 1,483,435 genotyped SNPs were available for meta-analysis. Genome-wide significance was defined as a $p < 5 \times 10^{-8}$ based on a Bonferroni correction for an assumed million independent variants in the human genome (Johnson et al., 2010). QQ and Manhattan plots were created using ggplot2 in R (Wickham, 2016).

Genetic risk score (GRS) analysis was conducted to investigate the collective contribution of schizophrenia risk loci to RA risk. Weighted GRS (wGRS) was performed in the RA (Okada et al., 2014) dataset, based on SNPs extracted from the schizophrenia (Li et al., 2017) dataset meeting $p$ value thresholds of 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.9. At each threshold, SNPs with schizophrenia association $p$ value below the threshold were used to construct wGRS in the RA dataset by summing the number of risk alleles at each SNP weighted by the natural logarithm of its effect size on schizophrenia or RA as appropriate. GRS analysis was done using the GRS function implemented in the gtx.summary module of the R package Genetics ToolBox (gtx-package, version 0.0.8). In this method, Nagelkerke's $R^2$ m is the (pseudo) variance explained in the testing dataset from the likelihood ratio test statistic that can be obtained under the regression model. Chi-square $\chi^2$ m test of independence was also used to determine all SNPs have independent effects. The gtx.summary module implements the summary statistic method described by International Consortium for Blood Pressure Genome-Wide Association et al., (2011) for approximating the regression of an outcome onto an additive GRS, using only single SNP association summary statistics extracted from GWAS results. This method is described in more detail in Dastani et al. (2012).

3  |  RESULTS

3.1  |  Meta-GWAS combining both RA and schizophrenia datasets

QQ plots showed deviations of $p$ values from the diagonal line in both RA-schizophrenia meta-GWAS and inverted meta-GWAS datasets. This indicates that $p$ values were smaller than expected by chance (Figure 1). The Manhattan plots showed a significant peak at the MHC locus on chromosome 6 (Figures 2 and 3) in both meta-GWAS datasets. After filtering for minor allele frequency (MAF < 0.01) and Hardy–Weinberg equilibrium (HWE) $p < 5 \times 10^{-8}$, the MHC locus was the only locus found above the genome-wide level of significant threshold in both RA-schizophrenia meta-GWAS and inverted meta-GWAS datasets. Regions with the significant associated variants have been visualized (Figures 4 and 5) using LocusZoom tool (Pruim et al., 2010; available from http://locuszoom.sph.umich.edu/).

3.2  |  Testing RA loci in schizophrenia GWAS datasets and schizophrenia loci in RA GWAS

No schizophrenia-associated locus was found to be associated with RA at a genome-wide level of significance.
(\(p < 5 \times 10^{-8}\)). However, 14 SNPs were nominally associated with RA \((p < 0.05);\) Table 2).

Examining the latest RA loci in schizophrenia GWAS (Li et al., 2017) showed no significant association at a genome-wide level of significance \((p < 5 \times 10^{-8})\) between RA loci and schizophrenia. However, eight SNPs showed minimal association with schizophrenia \((p < 0.05);\) Table 3.

### 3.3 Genetic risk scores

To examine the genetic relationship between RA and schizophrenia, the weighted genetic risk scores (wGRS) were calculated using the published summary statistics of the Li et al. (2017) data for schizophrenia and the Okada et al. (2014) data for RA. Schizophrenia risk loci derived from Li et al. (2017) GWAS data, were examined in the Okada et al. (2014) data and similarly RA risk loci derived from Okada et al. (2014) were tested in the Li et al. (2017) GWAS data. The wGRS for schizophrenia and RA cases and controls were calculated using the panel of SNPs and fitted a logistic regression model. A series of \(p\) value thresholds \((PT)\) were used to select RA and schizophrenia risk alleles for wGRS calculation for each set of SNPs. SNPs associated with schizophrenia at \(PT < 0.001\) explain only about 0.03% of the variance in RA status (Table 4 and Figure 6). RA-associated loci at \(PT < 0.001\) explain only about 0.004% of the variance in schizophrenia status (Table 4 and Figure 7). The variance in RA and schizophrenia explained by wGRS was calculated separately as pseudo \(R^2\).

Logistic regression analysis was performed to examine the associations with wGRS at the different significance thresholds of SNPs list. First, we tested whether the schizophrenia GRS predicted variance in RA disease state in a logistic model and then, we tested whether the RA GRS predicted variance in schizophrenia disease state in a logistic model. There was no evidence for statistically significant association \((p > 0.179\) and \(p > 0.248\), respectively), and, therefore, the wGRS between RA and schizophrenia is not stronger than it would be expected by chance.

### 4 DISCUSSION

Meta-GWAS was performed to investigate shared association loci between RA and schizophrenia at the genome-wide scale. Two different meta-GWAS were performed. The first meta-GWAS consisted of the whole RA GWAS data combined with the schizophrenia GWAS dataset. This aimed to identify RA-schizophrenia shared association loci with the similar effects at the genome-wide scale. Another (inverted)
meta-GWAS was performed to provide a new opportunity to identify RA-schizophrenia shared association loci with opposite effects at the genome-wide scale. Interestingly, significantly associated loci in both meta-GWAS analyses were within the MHC region on the chromosome 6. However, stronger association was found in the inverse-meta-GWAS analysis. This observed strengthening evidence for the association of MHC region in the combined RA-schizophrenia data with the inverted-effect supporting a genetic basis to the inverse correlation between RA and schizophrenia.

The finding of this study is consistent with the well-established role of the MHC in the etiology of both RA and schizophrenia. The MHC locus is best known for its role in immunity but the genes and molecular mechanisms accounting for this association need to be identified. Implication of the \( HLA-DRB1 \) gene in schizophrenia supports the role of the immune system in the development of schizophrenia (Feigenson et al., 2014). Sekar et al. (2016) reported the distinct association of schizophrenia with variation in the MHC locus involving structurally diverse alleles of the complement component 4 (\( C4 \)) genes that affect the expression of \( C4A \) and \( C4B \) genes in the brain (Sekar et al., 2016). Lee et al. (2015) reported that variants in immune response pathways such as \( HLA \) loci could play different roles in different tissues and/or in response to different challenges (Lee et al., 2015). The result of meta-GWAS conducted in this study is also supported by the report of Watanabe et al. (2009; Watanabe et al., 2009) that \( HLA-DRB1 \) is associated with both RA and schizophrenia. Given the strong association of the MHC locus with RA, achieving genome-wide significance in combined RA-schizophrenia is not that remarkable and is likely driven by the strong association between RA and the MHC locus. We recognize that genes and haplotypes mapped within the MHC region have a complex linkage structure and given that their
structures and functions are highly divers, the investigation of their role in autoimmune- and neurological-mediated complex diseases such as RA and schizophrenia have proved to be challenging (Lokki & Paakkanen, 2019; Muniz-Castrillo, Vogrig, & Honnorat, 2020). Combining the RA and schizophrenia datasets increased the statistical power of meta-analysis by maximizing the sample size but it would also create a more heterogeneous cohort due to the combination of patients with RA and schizophrenia. Our results of meta-GWAS are consistent with the role of the MHC region in the genetic etiology of both RA and schizophrenia disorders (Zamanpoor, 2019, 2020). This suggests that either schizophrenia has an autoimmune basis and/or RA has an active neurological component (Kipnis, Cardon, Strous, & Schwartz, 2006; Torrey & Yolken, 2001). Several studies have reported the contribution of an active immunological system in the etiology of schizophrenia (de la Fontaine et al., 2006). Common inflammatory mechanisms as part of the common pathogenetic hypothesis between RA and schizophrenia are supported by the role of immune dysregulation and alterations in neuroinflammatory pathways in schizophrenia (Altamura et al., 2014). Cytokines interact with monoaminergic system mediators such as dopamine, serotonin and glutamate, and the autonomic nervous system (Altamura et al., 2014; Kim, Jung, Myint, Kim & Park, 2007). Both schizophrenia and RA are associated with an imbalance in inflammatory cytokines suggesting a possible target for pharmacological treatments (Altamura et al., 2014). The positive effect of nonsteroidal anti-inflammatory drugs to reduce psychotic symptom severity, supports the possibility of inflammatory mechanisms underlying schizophrenia pathogenesis (Malavia et al., 2017). This immune-based anti-inflammatory therapeutic approach opens interesting perspectives for immune therapy in schizophrenia (Müller, Weidinger, Leitner & Schwarz, 2016).

A growing list of the confirmed non-HLA susceptibility loci is associated with RA and schizophrenia at a genome-wide level of significance. In this study, RA-associated variants were tested for association in schizophrenia GWAS data (Li et al., 2017) and schizophrenia-associated variants were tested for association in RA GWAS data (Okada et al., 2014). However, there was no evidence of association for confirmed non-HLA susceptibility loci with both RA and schizophrenia in our study. This suggests that the MHC locus might be mainly responsible for the inverse relationship between RA and schizophrenia and also that non-HLA loci have a weaker effect that these GWAS datasets were still underpowered to detect. Although there were some loci with minimal association with both RA and schizophrenia (listed in Tables 2 and 3), these loci confer a weaker effect (0.67 < OR < 1.5) and, therefore, were of less interest. However, this might be worthy of further investigation.

FIGURE 5 LocusZoom plot showing the most significant associated region within the MHC region on chromosomes 6 in RA-schizophrenia inverted meta-GWAS dataset.
The wGRS analysis in this study has shown that variance in RA status cannot be explained or predicted by schizophrenia risk alleles. Results of the wGRS analysis in this study provided no evidence for the contribution of schizophrenia risk loci to RA risk, and therefore, would not support the contribution of shared genetic factors in inverse correlation between schizophrenia and RA. The findings of our study are consistent with that of Euesden et al. (2015) and conclude that GRS cannot provide any genetic evidence to support the inverse correlation between schizophrenia and RA. Our finding is also consistent with several lines of evidence in recent linkage disequilibrium score regression studies, conducted by Pouget et al., 2019 (Pouget et al., 2019; \( rg = -0.032, p = 0.78 \)) and Tylee et al., (2018) (\( rg = -0.0301, p = 0.68 \)), reporting that there is no significant genome-wide genetic correlations between schizophrenia and RA.

It is likely that other nongenetic and environmental factors may contribute to the inverse relationship between RA and schizophrenia, which is beyond the scope of this study. As suggested by Euesden et al. (2015), one of such factors could be the effect of medication. Most of antipsychotic medications have an anti-inflammatory effect. Given that patients with schizophrenia have a much earlier age at onset in comparison to RA patients, it is likely that by age at onset for RA, schizophrenia patients are medicated which could have a protective effect on development of RA later in life. These findings would warrant further investigation for the causal effects between RA and schizophrenia using Mendelian randomization.

### Table 2

Association analysis of schizophrenia loci at genome-wide level of significance from Li et al. (2017) in RA GWAS (Okada et al., 2014).

| SNP       | Chr | Position   | Closest Gene | OR (SE)         | \( p \) value | Disease | Effect direction |
|-----------|-----|------------|--------------|-----------------|---------------|---------|-----------------|
| rs115329265 | 6   | 28,712,247 | NOP56P1, RPSAP2 | 1.210 (0.015)  | 5.02E-36      | SZ      | Susceptible     |
| rs66691851  | 3   | 136,154,828 | STAG1        | 0.926 (0.010)  | 4.17E-15      | SZ      | Protective      |
| rs1198589   | 1   | 98,550,411  | MIR137       | 0.907 (0.013)  | 1.19E-13      | SZ      | Protective      |
| rs2577831   | 3   | 52,628,056  | PBRM1        | 0.936 (0.009)  | 4.53E-13      | SZ      | Protective      |
| rs3814881   | 16  | 30,000,901  | TAOK2        | 0.936 (0.009)  | 8.41E-13      | SZ      | Protective      |
| rs9607782   | 22  | 41,587,556  | EP300        | 1.090 (0.012)  | 1.01E-12      | SZ      | Susceptible     |
| rs2970610   | 1   | 44,097,530  | PTPRF        | 1.072 (0.010)  | 1.24E-12      | SZ      | Susceptible     |
| rs61882743  | 11  | 46,548,754  | AMBRA1       | 0.914 (0.013)  | 6.99E-12      | SZ      | Protective      |
| rs112537273 | 8   | 38,248,306  | LETM2        | 1.077 (0.011)  | 1.06E-11      | SZ      | Susceptible     |
| rs2381759   | 2   | 146,428,031 | TEX41        | 0.929 (0.013)  | 8.63E-09      | SZ      | Protective      |
| rs111782145 | 6   | 30,873,508  | GTF2H4       | 0.93 (0.05)    | 0.0046        | RA      | Protective      |
| rs10894308  | 11  | 130,891,895 | SNX19        | 0.947 (0.010)  | 2.09E-08      | SZ      | Protective      |
| rs2247870   | 5   | 90,151,589  | ADGRV1       | 1.052 (0.009)  | 2.54E-08      | SZ      | Susceptible     |
| rs13266463  | 8   | 143,403,693 | TSNARE1      | 0.947 (0.010)  | 2.25E-08      | SZ      | Protective      |

Abbreviations: A1, minor allele; A2, major allele; Chr, chromosome; OR, odds ratio; SE, standard error; SZ, schizophrenia.
Another possible factor could be that many patients with schizophrenia might die before age of onset of RA due to shortened life expectancy in patients with schizophrenia.

There are some limitations in our study similar to previous studies investigated the genetic association between RA and schizophrenia, as it was discussed above, there is a substantial difference in the age of onset between RA and schizophrenia (Benros et al., 2014; Euesden et al., 2015). We analyzed data generated from different studies using different microarray platforms and this might also present another limitation. The study's power that is based on the sample size of any given study can affect the

**Table 3** Association analysis of RA loci at genome-wide level of significance from Okada et al. (2014) in schizophrenia GWAS (Li et al., 2017).

| SNP       | Chr | Position   | Closest Gene | OR (SE)    | p value     | Disease | Effect direction |
|-----------|-----|------------|--------------|------------|-------------|---------|-----------------|
| rs8032939 | 15  | 38,834,033 | RASGRP1      | 0.89 (0.03) | 2.40E-12    | RA      |                 |
| rs8032939 |     |            |              | 0.962 (0.011) | 0.0007    | SZ      | Protective     |
| rs28411352| 1   | 38,278,579 | MTF1, INPP5B | 1.11 (0.05) | 5.20E-09    | RA      | Susceptible    |
|           |     |            |              | 0.964 (0.011) | 0.0011    | SZ      |                 |
| rs2228145 | 1   | 154,426,970| IL6R         | 1.07 (0.04) | 4.50E-06    | RA      | Susceptible    |
|           |     |            |              | 1.025 (0.01) | 0.0119    | SZ      | Protective     |
| rs9826828 | 3   | 136,402,060| STAG1, IL20RB| 1.42 (0.185)| 9.20E-08   | RA      | Susceptible    |
|           |     |            |              | 1.074 (0.036) | 0.0497 | SZ      | Susceptible    |
| rs67250450| 7   | 28,174,986 | JAZF1        | 1.10 (0.05) | 1.90E-06    | RA      | Susceptible    |
|           |     |            |              | 0.968 (0.013) | 0.0098 | SZ      | Protective     |
| rs331463  | 11  | 36,501,787 | TRAF6, RAG1/2| 0.90 (0.03) | 5.70E-06    | RA      | Protective     |
|           |     |            |              | 1.043 (0.014) | 0.0026 | SZ      | Susceptible    |
| rs1950897 | 14  | 68,760,141 | RAD51B       | 1.09 (0.04) | 2.50E-07    | RA      | Susceptible    |
|           |     |            |              | 0.969 (0.011) | 0.0049 | SZ      | Protective     |
| chr21:35928240 | 21 | 35,928,240 | RCAN1        | 0.88 (0.04) | 2.90E-07    | RA      | Protective     |
|           |     |            |              | 0.967 (0.016) | 0.0364 | SZ      | Protective     |

**Table 4** Schizophrenia GRS across thresholds and variance in RA status explained, and RA GRS across thresholds and variance in schizophrenia status explained.

| p threshold | Number of SNPs | GRS for RA in schizophrenia | GRS for schizophrenia in RA |
|-------------|----------------|-----------------------------|-----------------------------|
|             | Pseudo R^2     | p value                     | Pseudo R^2                  | p value |
| 0.0001      | 57             | 0.35                        | 0.035                       | 0.811   | 0.00439 | 0.795 |
| 0.001       | 135            | 0.032                       | 0.635                       | 0.00354 | 0.309  |
| 0.01        | 286            | 0.028                       | 0.241                       | 0.00466 | 0.475  |
| 0.05        | 4059           | 0.040                       | 0.435                       | 0.00243 | 0.373  |
| 0.1         | 5964           | 0.042                       | 0.349                       | 0.00301 | 0.514  |
| 0.2         | 7025           | 0.034                       | 0.423                       | 0.00381 | 0.685  |
| 0.3         | 8325           | 0.042                       | 0.403                       | 0.0029  | 0.248  |
| 0.4         | 11778          | 0.041                       | 0.179                       | 0.0033  | 0.428  |
| 0.5         | 15955          | 0.037                       | 0.332                       | 0.00392 | 0.575  |
| 0.6         | 17623          | 0.046                       | 0.253                       | 0.00362 | 0.353  |
| 0.7         | 19812          | 0.042                       | 0.724                       | 0.00421 | 0.470  |
| 0.8         | 21812          | 0.039                       | 0.789                       | 0.0043  | 0.884  |
| 0.9         | 24301          | 0.040                       | 0.647                       | 0.00504 | 0.377  |

Abbreviations: A1, minor allele; A2, major allele; Chr, chromosome; OR, odds ratio; SE, standard error; SZ, schizophrenia.

analysis. Another possible factor could be that many patients with schizophrenia might die before age of onset of RA due to shortened life expectancy in patients with schizophrenia.

There are some limitations in our study similar to previous studies investigated the genetic association between RA and schizophrenia, as it was discussed above, there is a substantial difference in the age of onset between RA and schizophrenia (Benros et al., 2014; Euesden et al., 2015). We analyzed data generated from different studies using different microarray platforms and this might also present another limitation. The study’s power that is based on the sample size of any given study can affect the
ability to detect the true correlation between genetic effects in GRS analysis (Euesden et al., 2015). As we discussed earlier, the most significantly associated loci were among the MHC region, which were excluded in our study, and this might be an important caveat in this study.

**ACKNOWLEDGMENT**
This research was supported by University of Otago, New Zealand. Authors thank Professors Tony Merriman and Ian Morison from University of Otago, New Zealand for their scientific advice in this study.

**CONFLICT OF INTEREST**
Authors declare that there is no conflict of interest.

**AUTHOR CONTRIBUTION**
MZ carried out the experiment and wrote the manuscript. HG and MDO verified the analytical methods and reviewed the
manuscript drafts. All authors discussed the results and significantly contributed to the final manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study were derived from the following resources available in the public domain: http://gwas.bio-x.cn/, http://plaza.umin.ac.jp/~yokada/datasource/software.htm, and https://www.wtccc.org.uk/info/access_to_data_samples.html.

ORCID
Mansour Zamanpoor https://orcid.org/0000-0003-1299-9619

REFERENCE
Altmura, A. C., Buoli, M., & Pozzoli, S. (2014). Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. *Psychiatry Clin Neurosci*, 68, 21–36.

Allebeck, P., Rodvall, Y., & Wistedt, B. (1985). Incidence of rheumatoid arthritis among patients with schizophrenia, affective psychosis and neurosis. *Acta Psychiatrica Scandinavica*, 71, 615–619.

Baldwin, J. A. (1980). Schizophrenia and physical disease: a preliminary analysis of the data from the Oxford Record Linkage Study. In H. G. Lancaster (Ed.), *The Biochemistry of Schizophrenia and Addiction*. Search of a Common Factor, (pp. 297-318). Dordrecht, the Netherlands: MTP.

Benros, M. E., Pedersen, M. G., Rasmussen, H., Eaton, W. W., Nordentoft, M., & Mortensen, P. B. (2014). A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis. *American Journal of Psychiatry*, 171(2), 218–226. https://doi.org/10.1176/appi.ajp.2013.13010086

Chen, S.-J., Chao, Y.-L., Chen, C.-Y., Chang, C.-M., Wu, E.-H., Wu, C.-S., … Tsai, H.-J. (2012). Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study. *The British Journal of Psychiatry*, 200(5), 374–380.

Chen, S. F., Wang, L. Y., Chiang, J. H., Hsu, C. Y., & Shen, Y. C. (2019). Assessing whether the association between rheumatoid arthritis and schizophrenia is bidirectional: A nationwide population-based cohort study. *Scientific Reports*, 9(1), 1–9. https://doi.org/10.1038/s41598-018-38149-3

Ching Lok, E. Y., Mok, C. C., Cheng, C. W., & Chi Cheung, E. F. (2010). Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. *Psychosomatics*, 51(4), 338–338. e8. https://doi.org/10.1176/appi.ps.51.4.338

Dastani, Z., Hivert, M.-F., Timpson, N., Perry, J. R. B., Yuan, X., Scott, R. A., … Richards, J. B. (2012). Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. *PLoS Genet*, 8(3), e1002607. https://doi.org/10.1371/journal.pgen.1002607

de la Fontaine, L., Schwarz, M. J., Riedel, M., Dehning, S., Douhet, A., Spellmann, I., … Müller, N. (2006). Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms. *Psychiatry Research*, 144(1), 39–47. https://doi.org/10.1016/j.psychres.2006.01.006

Eaton, W. W., Byrne, M., Ewald, H., Mors, O., Chen, C. Y., Agerbo, E., & Mortensen, P. B. (2006). Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. *American Journal of Psychiatry*, 163, 521.

Eaton, W. W., Hayward, C., & Ram, R. (1992). Schizophrenia and rheumatoid arthritis: a review. *Schizophrenia Research*, 6(3), 181–192. https://doi.org/10.1016/0920-9964(92)90001-L

Eaton, W., Mortensen, P., Agerbo, E., Byrne, M., Mors, O., & Ewald, H. (2004). Crohn’s disease and schizophrenia: Population based case control study with linkage of Danish national registers. *British Medical Journal*, 328(7437), 438. https://doi.org/10.1136/bmj.328.7437.438

Euesden, J., Breen, G., Farmer, A., McGuffin, P., & Lewis, C. M. (2015). The relationship between schizophrenia and rheumatoid arthritis revisited: genetic and epidemiological analyses. *American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics*, 168B(2), 81–88. https://doi.org/10.1002/ajmg.b.32282

Feigenson, K. A., Kusneov, A. W., & Silverstein, S. M. (2014). Inflammation and the two-hit hypothesis of schizophrenia. *Neuroscience and Biobehavioral Reviews*, 38, 72–93. S0149-7634(13)00275-3[pii]

Gallego, J. A., Blanco, E. A., Husain-Krautter, S., Madeline Fagen, E., Moreno-Merino, P., Del ojo-Jimenez, J. A., … Malhotra, A. K. (2018). Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis. *Schizophr Res*.

Gorwood, P., Pouchot, J., Vinceneux, P., Puechbal, X., Flipo, R. M., De Bandt, M., … Rhumatisme, C. (2004). Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. *Schizophrenia Research*, 66(1), 21–29. https://doi.org/10.1016/s0920-9964(03)00017-3

Gorwood, P., Pouchot, J., Vinceneux, P., Puechbal, X., Flipo, R. M., De Bandt, M., & Ades, J. (2004). Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. *Schizophrenia Research*, 66(1), 21–29.

Helmick, C. G., Felson, D. T., Lawrence, R. C., Gabriel, S., Hirsch, R., Kwoh, C. K., … Stone, J. H. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. *Arthritis and Rheumatism*, 58(1), 15–25. https://doi.org/10.1002/art.23177

International Consortium for Blood Pressure Genome-Wide Association, S, Ehret, G. B., Munroe, P. B., Rice, K. M., Bochud, M., Johnson, A. D. … Johnson, T. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*, 478(7367), 103–109. https://doi.org/10.1038/nature10405

Janicijevic, S., Dejanovic, S., & Borovcanin, M. (2018). Interplay of brain-derived neurotrophic factor and cytokines in schizophrenia. *Serbian Journal of Experimental and Clinical Research* (published online ahead of print 2018). https://doi.org/10.1515/sjecr-2017-0031

Johnson, R. C., Nelson, G. W., Troyer, J. L., Lautenberger, J. A., Kessing, B. D., Winkler, C. A., & O’Brien, S. J. (2010). Accounting for multiple comparisons in a genome-wide association study (GWAS). *BMC Genomics*, 11, 724. https://doi.org/10.1186/1471-2164-11-724

Kim, Y. K., Jung, H. G., Myint, A. M., Kim, H., & Park, S. H. (2007). Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. *J Affect Disorder*, 104, 91–5.

Kipnis, J., Cardon, M., Strous, R. D., & Schwartz, M. (2006). Loss of autoimmune T cells correlates with brain diseases: possible
genes with schizophrenia. Journal of Human Genetics, 54(1), 62–65. https://doi.org/10.1038/jhg.2008.4

Wickham, H. (2016). ggplot2: elegant graphics for data analysis. Springer.

Willer, C. J., Li, Y., & Abecasis, G. R. (2010). METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics, 26(17), 2190–2191. https://doi.org/10.1093/bioinformatics/btq340

Wright, P., Nimgaonkar, V. L., Donaldson, P. T., & Murray, R. M. (2001). Schizophrenia and HLA: a review. Schizophrenia Research, 47(1), 1–12. https://doi.org/10.1016/S0920-9964(00)00022-0

Zamanpoor, M. (2019). The genetic pathogenesis, diagnosis and therapeutic insight of rheumatoid arthritis. Clinical Genetics, 95(5), 547–557. https://doi.org/10.1111/cge.13498

Zamanpoor, M. (2020). Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatric Genetics, 30(1), 1–9. https://doi.org/10.1097/YPG.000000000000245

How to cite this article: Zamanpoor M, Ghaedi H, Omrani MD. The genetic basis for the inverse relationship between rheumatoid arthritis and schizophrenia. Mol Genet Genomic Med. 2020;8:e1483. https://doi.org/10.1002/mgg3.1483